Products Categories
    Product Certification&
    Enterprise Certification

  • Ms.Alice
    Tel: 86-021-87891888

  • Mobile:
  • Tel:86-021-87891888
  • Fax:
  • URL:http://www.chinataigui-steroid.com/
  • Province/state:Shanghai
  • City:Shanghai
  • Street:Room168,The No 1 Building, No1520 FuXing Road,HuangPu area,Shanghai,China
  • MaxCard:
Home > Products >  Raloxifene Hydrochloride Anti Estrogen Raloxifene Hydrochloride Powder For Anti Cancer CAS 82640-04-8

Raloxifene Hydrochloride Anti Estrogen Raloxifene Hydrochloride Powder For Anti Cancer CAS 82640-04-8 CAS NO.82640-04-8

  • FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
  • Min.Order: 10 Gram
  • Payment Terms: T/T,MoneyGram,Other
  • Available Specifications:

    1(1-10)Gram

  • Product Details

Keywords

  • 82640-04-8
  • Raloxifene Hydrochloride
  • Anti Estrogen Powder

Quick Details

  • ProName: Raloxifene Hydrochloride Anti Estrogen...
  • CasNo: 82640-04-8
  • Molecular Formula: c28h29no4s
  • Appearance: white powder
  • Application: bodybuilding, muscle building
  • DeliveryTime: 5-8 days
  • PackAge: exquisite or according to your require...
  • Port: hongkong
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99%
  • Storage: Sealed, dry, microtherm
  • Transportation: DHL,TNT,FEDEX,HKEMS,UPS,etc
  • LimitNum: 10 Gram
  • Moisture Content: 0
  • Impurity: 0
  • email: taigui-alice@hotmail.com
  • skype: xu.alice55

Superiority

Raloxifene Hydrochloride Anti Estrogen Powder Raloxifene Hydrochloride For Anti Cancer CAS 82640-04-8

Details

cas no: 82640-04-8
molecular formula: c28h29no4s
molecular weight: 475.5992
appearance: white powder
purity: 99%
certification: iso 9001, usp, bp
specification: usp
uses: for osteoporosis prevention of postmenopausal women.
 
descritpion:
 
raloxifene (marketed as evista) is an oral selective estrogen receptor modulator (serm) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. it is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
 
this drug is different from hormones (including estrogens and progestins). it works by acting like estrogen (as a selective estrogen receptor modulator or serm) in some parts of the body. raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.
 
evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (serm) and belongs to the benzothiophene class of compounds. the biological actions of raloxifene are largely mediated through binding to estrogen receptors. this binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism).
 
application:
 
raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. it is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.for either osteoporosis treatment or prevention, supplemental calcium and/or vitamin d should be added to the diet if daily intake is inadequate.
 
raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.
 
raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.
may prevent or treat corticosteroid-induced bone loss. american college of rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
 
reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (star trial). no effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (star trial).
 
effect on breast cancer incidence in women with brca1 or brca2 genetic mutations not established. not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 not indicated for reduction in the risk of noninvasive breast cancer.

 

Details

our advantages:

 

1. shanghai taigui pharmaceutical technology co., ltd is a professional raw powder factory in china for
    over 10 years, all powders are factory directly supplying.

2. our products have exported to germany, norway, poland, finland, spain, uk, france, russia, usa,
    australia, japan, korea and many other countries, over 3000t each month.

3. professional team special for package and shipment and staring on tracking code 24hours for customs
    pass guaranteed. 100% pass to uk, norway, poland, spain, usa, canada, brazil; 98% pass to
    germany,russia, australia, new zealand.

4. most of powders are in stock, chargeable samples are available, could be shipped out within 24hours.

5. high quality, good price, fast and safety delivery. shipment by dhl, tnt, fedex, hkems, ups, etc.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog